(19)
(11) EP 2 379 597 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
30.11.2016 Bulletin 2016/48

(45) Mention of the grant of the patent:
10.08.2016 Bulletin 2016/32

(21) Application number: 09806144.3

(22) Date of filing: 22.12.2009
(51) International Patent Classification (IPC): 
C07K 16/28(2006.01)
 C12N 15/117(2010.01)
(86) International application number:
PCT/IL2009/001210
(87) International publication number:
WO 2010/073247 (01.07.2010 Gazette 2010/26)

(54)

EGFR-HOMING DOUBLE-STRANDED RNA VECTOR FOR SYSTEMIC CANCER TREATMENT

AUF EGFR ZIELENDER DOPPELSTRÄNGIGER RNA-VEKTOR ZUR SYSTEMISCHEN BEHANDLUNG VON KREBS

VECTEUR D'ARN BICATÉNAIRE CIBLANT EGFR POUR LE TRAITEMENT SYSTÉMIQUE DU CANCER

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(30) Priority: 22.12.2008 US 139698 P

(43) Date of publication of application:
26.10.2011 Bulletin 2011/43

(60) Divisional application:
16177258.7 / 3098239

(73) Proprietor: Levitzki, Alexander
9371411 Jerusalem (IL)

(72) Inventors:
  • LEVITZKI, Alexander
    9371411 Jerusalem (IL)
  • SHIR, Alexei
    9781207 Jerusalem (IL)

(74) Representative: Vossius & Partner Patentanwälte Rechtsanwälte mbB 
Siebertstrasse 3
81675 München
81675 München (DE)


(56) References cited: : 
WO-A2-2004/045491
   
  • SHIR ALEXEI ET AL: "EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice." PLOS MEDICINE JAN 2006 LNKD- PUBMED:16318410, vol. 3, no. 1, January 2006 (2006-01), page E6, XP002579432 ISSN: 1549-1676 cited in the application
  • FRIEDRICH I ET AL: "RNA MOLECULES AS ANTI-CANCER AGENTS" SEMINARS IN CANCER BIOLOGY, SAUNDERS SCIENTIFIC PUBLICATIONS, PHILADELPHIA, PA, US LNKD- DOI:10.1016/J.SEMCANCER.2004.04.001, vol. 14, no. 4, 1 August 2004 (2004-08-01), pages 223-230, XP009049584 ISSN: 1044-579X
  • CICERI F ET AL: "Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation" BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US LNKD- DOI:10.1182/BLOOD-2006-05-023416, vol. 109, no. 11, 1 June 2007 (2007-06-01), pages 4698-4707, XP002526048 ISSN: 0006-4971 [retrieved on 2007-02-27] cited in the application
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).